A. Jaslowski

发表

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.

KyungMann Kim, J. Schiller, Paul E Koch, 2003, Lung cancer.

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Scott E. Smith, Sonali M. Smith, J. Leonard, 2017, The Lancet. Haematology.

Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy

P. Novotny, J. Sloan, C. Loprinzi, 2012, Cancer.

Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.

P. Novotny, J. Sloan, C. Loprinzi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy

E. Perez, M. Goetz, T. Hobday, 2008 .

Phase III double‐blind, placebo‐controlled study of gabapentin for the prevention of delayed chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance)

J. Sloan, C. Loprinzi, L. Kottschade, 2014, Cancer.

Pemetrexed and Gemcitabine for Biliary Tract and Gallbladder Carcinomas: a North Central Cancer Treatment Group (NCCTG) Phase I and II Trial, N9943

N. Foster, J. Kugler, S. Alberts, 2007, Journal of gastrointestinal cancer.

A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA.

J. Sloan, D. Moore, C. Loprinzi, 2011, The journal of supportive oncology.

A Phase III Randomized, Double Blind, Placebo-Controlled Study of Pilocarpine for Vaginal Dryness: NCCTG study N04CA 1

J. Sloan, C. Loprinzi, R. Zon, 2011 .

Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease

R. Sun, A. Haase, P. Rácz, 1999, Journal of Virology.

NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: Phase II results

N. Foster, J. Kugler, S. Alberts, 2007 .

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

C. Paweletz, P. Jänne, E. Vokes, 2019, JAMA oncology.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)

J. Kirkwood, T. Kuzel, D. Lawrence, 2017, Cancer.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

J. Wolchok, M. Atkins, J. Sosman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of nab‐paclitaxel (ABI‐007) and carboplatin in patients with unresectable stage IV melanoma

R. McWilliams, V. Suman, S. Markovic, 2011, Cancer.

A randomized phase 2 study of temozolomide and bevacizumab or nab‐paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma

R. McWilliams, V. Suman, S. Markovic, 2013, Cancer.

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

E. Perez, T. Hobday, B. Laplant, 2016, Clinical breast cancer.

A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial

J. Sloan, D. Moore, C. Loprinzi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).

C. Paweletz, P. Janne, E. Vokes, 2018, Annals of Oncology.

Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5.

P. Novotny, C. Loprinzi, J. Kugler, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of yoga, cognitive behavioral therapy, and a behavioral placebo on sleep: A nationwide multicenter phase III RCT in cancer survivors.

C. Heckler, I. Kleckner, K. Loh, 2021 .

Effects of YOCAS yoga, cognitive behavioral therapy, and survivorship health education on insomnia: A URCC NCORP Research Base Phase III RCT in 740 cancer survivors.

S. Mohile, I. Kleckner, K. Loh, 2020, Journal of Clinical Oncology.

Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)

D. Moore, N. Foster, K. Rowland, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed and Gemcitabine for Biliary Tract and Gallbladder Carcinomas: a North Central Cancer Treatment Group (NCCTG) Phase I and II Trial, N9943

N. Foster, J. Kugler, S. Alberts, 2007, Journal of gastrointestinal cancer.

NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma.

A. Grothey, E. Hedrick, A. Jaslowski, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma: A North Central Cancer Treatment Group Study (N0775).

R. McWilliams, S. Markovic, V. Suman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.